Time to look beyond just lowering the serum concentration of low density lipoprotein - High density lipoprotein levels are also important

Journal of The Royal Society for the Promotion of Health

Volumn 121, Issue 2, 2001, Pages 98-101

  Nair, D R ^a   Wierzbicki, A S ^b   Mikhailidis, D P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cholesterol; Coronary heart disease (CHD); High density lipoprotein (HDL); Low density lipoprotein (LDL)

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; STATIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG USE; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; POPULATION RESEARCH; PRACTICE GUIDELINE; PREDICTION; REVIEW; RISK ASSESSMENT; SERUM; TREATMENT PLANNING;

EID: 0034939113     PISSN: 14664240     EISSN: None     Source Type: Journal    
DOI: 10.1177/146642400112100210     Document Type: Review

References (30)

1. Relation of high density lipoprotein cholesterol and triglycerides to the incidence of atherosclerotic coronary artery disease (the PROCAM experience)
2. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy
3. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
4. Epidemiological aspects of high density lipoprotein cholesterol.
5. Insulin resistance, high prevalence of diabetes, and cardiovascular risk in immigrant Asians. Genetic or environmental effect?
6. Are drugs within a class interchangeable?
7. Bezafibrate: Treating hyperlipidaemias as well as other cardiovascular risk factors
8. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the air force/texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS)
9. Action of atorvastatin in combined hyperlipidemia
10. Simvastatin increases HDL-C and apolipoprotein A-1 levels significantly more than atorvastatin
11. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
12. Relationship of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians
13. HDL-cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simvastatin
14. Treatment of dyslipidaemias in patients with established vascular disease: A review of the fibrates
15. Ischaemic heart disease in South Asians - The ethnic difference
16. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients
17. Beneficial effect of moderate alcohol consumption on vascular disease: Myth or reality?
18. Statin + fibrate combination therapy: Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease
19. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the scandinavian simvastatin survival study (4S)
20. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
21. High-density lipoprotein cholesterol and coronary artery disease: Survey of the evidence
22. Gem-fibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
23. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
24. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study
25. Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety
26. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
27. Coronary and cardiovascular risk estimation for primary prevention: Validation of a new Sheffield table in the 1995 Scottish health survey population
28. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia
29. More on statins and fibrinogen
30. Joint British recommendations on prevention of coronary heart disease in clinical practice